CA3048494C - Methodes de traitement des maladies cardiovasculaires - Google Patents

Methodes de traitement des maladies cardiovasculaires

Info

Publication number
CA3048494C
CA3048494C CA3048494A CA3048494A CA3048494C CA 3048494 C CA3048494 C CA 3048494C CA 3048494 A CA3048494 A CA 3048494A CA 3048494 A CA3048494 A CA 3048494A CA 3048494 C CA3048494 C CA 3048494C
Authority
CA
Canada
Prior art keywords
dapansutrile
baseline
acute
pericarditis
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3048494A
Other languages
English (en)
Other versions
CA3048494A1 (fr
Inventor
Carlo MARCHETTI
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Priority claimed from PCT/US2018/012625 external-priority patent/WO2018129347A1/fr
Publication of CA3048494A1 publication Critical patent/CA3048494A1/fr
Application granted granted Critical
Publication of CA3048494C publication Critical patent/CA3048494C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une méthode destinée à traiter les maladies cardiovasculaires telles que l'infarctus aigu du myocarde, l'athérosclérose, l'insuffisance cardiaque, l'accident vasculaire cérébral, la thrombose, la cardite (y compris la myocardite aiguë, la péricardite aiguë et la péricardite complexe), le rejet d'allogreffe cardiaque, la cardiomyopathie et les maladies vasculaires périphériques. La méthode comprend l'administration à un sujet en ayant besoin de dapansutrile, en une quantité efficace. L'administration par voie orale constitue une voie d'administration préférée.
CA3048494A 2017-01-06 2018-01-05 Methodes de traitement des maladies cardiovasculaires Active CA3048494C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762443387P 2017-01-06 2017-01-06
US62/443,387 2017-01-06
US201762506843P 2017-05-16 2017-05-16
US62/506,843 2017-05-16
PCT/US2018/012625 WO2018129347A1 (fr) 2017-01-06 2018-01-05 Méthodes de traitement des maladies cardiovasculaires

Publications (2)

Publication Number Publication Date
CA3048494A1 CA3048494A1 (fr) 2018-07-12
CA3048494C true CA3048494C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US12318361B2 (en) Methods for treating cardiovascular diseases
Direct Inhibition of δ-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
US20080032933A1 (en) Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
US10583103B2 (en) Method of treating heart failure with preserved ejection fraction with probenecid
JP7830313B2 (ja) アルコール性肝炎の処置
Greenberg et al. Association between the exercise ejection fraction response and systolic wall stress in patients with chronic aortic insufficiency.
WO2007053610A2 (fr) Traitement de la fibrillation auriculaire a base de pirfenidone
JP2014533697A (ja) デフェリプロンを用いた処置方法
CN108042517A (zh) 用于治疗缺血性损伤的半胱胺和/或胱胺
US10456439B2 (en) NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation
EP3897661A1 (fr) Carboxymaltose ferrique utilisé dans le traitement d'une insuffisance cardiaque et dans le traitement d'une congestion dans une insuffisance cardiaque
JP2025513337A (ja) 心原性ショック前および心原性ショックの処置のためのイスタロキシムを含む静脈内注入製剤
US20260027094A1 (en) Use of pyridone derivative
US20050272741A1 (en) Novel methods of treatment for Fontan patients with protein losing enteropathy
WO2025128432A1 (fr) Istaroxime et dérivés métabolites associés pour réduire le risque d'arythmie myocardique aiguë
Lebedev et al. JOURNAL OF ARRHYTHMOLOGY
US20230190708A1 (en) Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition
Kulak et al. Advances in understanding, diagnosis and targeting ATTR cardiomyopathy: a review
CN119564700A (zh) 帕珠沙星甲磺酸盐在制备治疗急性心肌梗死的药物的用途
Joshi et al. Hypertrophic Cardiomyopathy
Rajan et al. Ventricular septal rupture complicating acute myocardial infarction following percutaneous coronary intervention